These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1673248)

  • 1. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
    Eden RJ; Costall B; Domeney AM; Gerrard PA; Harvey CA; Kelly ME; Naylor RJ; Owen DA; Wright A
    Pharmacol Biochem Behav; 1991 Jan; 38(1):147-54. PubMed ID: 1673248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
    Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A68930: a potent agonist selective for the dopamine D1 receptor.
    DeNinno MP; Schoenleber R; MacKenzie R; Britton DR; Asin KE; Briggs C; Trugman JM; Ackerman M; Artman L; Bednarz L
    Eur J Pharmacol; 1991 Jun; 199(2):209-19. PubMed ID: 1683288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
    Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Wang Y; Bouabid S; Darvas M; Zhou FM
    Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.
    Rupniak NM; Boyce S; Steventon M; Iversen SD
    Clin Neuropharmacol; 1992 Aug; 15(4):307-9. PubMed ID: 1355407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro.
    Arnt J; Hyttel J; Sánchez C
    Eur J Pharmacol; 1992 Mar; 213(2):259-67. PubMed ID: 1355737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.